Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer

To determine whether luteinising hormone‐releasing hormone (LHRH) agonist, ATRIGEL® polymer‐delivered, subcutaneous, leuprolide acetate (ADSC‐LA), formulations suppressed serum testosterone to concentrations of ≤20 ng/dL.

[1]  D. Dearnaley,et al.  Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. , 2015, Journal of Clinical Oncology.

[2]  N. Eckstein,et al.  Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer , 2014, European Journal of Clinical Pharmacology.

[3]  C. Fiori,et al.  Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. , 2013, Clinical genitourinary cancer.

[4]  B. Shayegan,et al.  Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[5]  A. Heijboer,et al.  Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. , 2012, The Journal of urology.

[6]  L. Reis,et al.  Goserelin versus leuprolide in the chemical castration of patients with prostate cancer , 2012, International Urology and Nephrology.

[7]  M. Marberger,et al.  Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. , 2010, Clinical therapeutics.

[8]  M. Perachino,et al.  Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone‐releasing hormone therapy: prognostic significance? , 2010, BJU international.

[9]  A. Orsola,et al.  Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. , 2007, The Journal of urology.

[10]  J. Morote,et al.  Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer , 2006, Urologia Internationalis.

[11]  E. Crawford,et al.  A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. , 2003, The Journal of urology.

[12]  O. Sartor,et al.  An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. , 2003, Urology.

[13]  E. Loizides,et al.  A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. , 2002, Clinical therapeutics.

[14]  R. Harkaway,et al.  A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. , 2002, The Journal of urology.

[15]  D. Gleason,et al.  A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. , 2001, Urology.

[16]  B. Lytton.  Prostate cancer: a brief history and the discovery of hormonal ablation treatment. , 2001, The Journal of urology.

[17]  M. Resnick,et al.  Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. , 2000, Urology.

[18]  R. Cornum,et al.  Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. , 2000, The Journal of urology.

[19]  M. Oefelein.  Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. , 1998, The Journal of urology.

[20]  C. Huggins.  EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE. , 1942, Annals of surgery.